The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye disease treatment had failed.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
ASX-listed biotech Opthea says it has terminated the second of its two trials of drugs to treat a common eye disease, delivering a near mortal blow to shareholders who had already written down the majority of their investments.
The company said on Monday that a second phase 3 trial “did not meet its primary endpoint” after disappointing investors only last week with the news that a first phase 3 trial had failed.
Fetching latest articles
Original URL: https://www.afr.com/markets/equity-markets/opthea-in-active-talks-with-funders-after-second-trial-fails-20250331-p5lnx7
